Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which your immune system mistakenly attacks healthy tissue throughout your body. It can affect nearly every organ, including the skin, joints, kidneys, brain, heart, and lungs. Modern treatment has dramatically improved outcomes: about 93% of people with SLE survive at least five years after diagnosis, and 83% survive at least ten years.
How Lupus Attacks the Body
In a healthy immune system, white blood cells learn to distinguish your own tissue from foreign invaders like bacteria and viruses. In SLE, that distinction breaks down. Certain immune cells, particularly B cells and T cells, become overactive and start producing antibodies that target your own DNA and proteins. These self-targeting antibodies, called autoantibodies, are the central drivers of the disease.
Autoantibodies bind to fragments of your own cells, forming clumps called immune complexes. These complexes deposit in tissues, especially the kidneys, blood vessels, and skin, where they trigger inflammation and attract more immune cells. This creates a feedback loop: damaged cells release more cellular debris, which stimulates more autoantibody production, which causes more damage. A signaling molecule called type I interferon acts as an accelerant in this cycle, ramping up immune activation and pushing B cells to produce even more autoantibodies.
Common Symptoms by Organ System
SLE is sometimes called “the great imitator” because its symptoms overlap with many other conditions. They also tend to come and go in waves, known as flares. The most recognizable symptoms include:
- Joints and muscles: Pain, stiffness, and swelling in multiple joints, often with at least 30 minutes of morning stiffness. This is one of the most common reasons people first see a doctor.
- Skin: A butterfly-shaped rash across the cheeks and nose is the classic sign, but lupus can also cause disc-shaped scaly patches, hair loss, and mouth sores. Rashes often worsen with sun exposure.
- General: Persistent fatigue and low-grade fever are extremely common and often the most disruptive symptoms day to day.
- Kidneys: Inflammation can silently damage the kidneys, sometimes showing up only as protein in the urine before any symptoms appear.
- Brain and nervous system: Headaches, difficulty concentrating, memory problems, and in more severe cases, seizures or psychosis.
- Heart and lungs: Inflammation of the lining around the heart or lungs can cause chest pain and shortness of breath. People with SLE also have a higher risk of heart attacks over time.
- Blood: Low red blood cell counts (anemia), low platelet counts that increase bleeding risk, and blood clots.
- Circulation: Fingers and toes that turn white or blue in cold temperatures or during stress, a phenomenon called Raynaud’s.
How SLE Is Diagnosed
There is no single test that confirms lupus. Diagnosis relies on a combination of blood work and clinical signs, guided by a classification system developed jointly by the European and American rheumatology societies in 2019.
The first step is a blood test called ANA (antinuclear antibody). A positive ANA at a level of 1:80 or higher is required before the other criteria are even considered. ANA is sensitive but not specific, meaning many people with a positive ANA don’t have lupus. It simply opens the door to further evaluation.
From there, doctors assess a point-based system spanning several clinical and immunologic categories. Each finding carries a different weight. Joint involvement scores 6 points. A butterfly rash scores 6. Kidney biopsy showing severe inflammation scores 10. Certain lupus-specific antibodies (anti-double-stranded DNA or anti-Smith) score 6 each. Low levels of complement proteins, which get consumed during immune complex formation, score 3 to 4. A total of 10 or more points, with at least one clinical sign, meets the classification threshold for SLE. Importantly, these findings don’t all need to be present at the same time. Lupus often reveals itself gradually over months or years.
Kidney Involvement
Kidney disease is one of the most serious complications of SLE. Clinically evident kidney problems develop in up to half of all SLE patients, and the risk is not equal across populations. Kidney involvement occurs in 34 to 51 percent of Black patients, 31 to 43 percent of Hispanic patients, and 33 to 55 percent of Asian patients, compared with 14 to 23 percent of white patients.
Lupus nephritis is classified into six stages based on kidney biopsy findings, ranging from minimal changes in the filtering units (class I) to advanced scarring (class VI). The most concerning forms, classes III and IV, involve widespread inflammation of the kidney’s filtering structures and require aggressive treatment. Because kidney damage can progress silently, regular urine and blood tests to monitor kidney function are a critical part of living with SLE.
Treatment Approach
Hydroxychloroquine is the backbone of SLE treatment. Originally developed as an antimalarial drug, it reduces flares, protects against organ damage, and improves long-term survival. Current guidelines recommend it for virtually every SLE patient at a target dose based on body weight. The main long-term concern is a small risk of retinal damage, which is monitored with regular eye exams.
When hydroxychloroquine alone isn’t enough to control the disease, the next step typically involves adding an immunosuppressive medication to quiet the overactive immune system. For moderate to severe disease, short courses of steroids are often used to bring flares under control quickly, but the goal is always to taper the steroid dose as low as possible, ideally below 5 mg per day or off entirely, because of the significant side effects steroids carry over time.
Two newer biologic medications have broadened treatment options significantly. Both work by targeting specific parts of the immune system rather than suppressing it broadly. One blocks the survival signal that keeps autoantibody-producing B cells alive. The other blocks the type I interferon pathway that fuels the inflammatory cycle. Current guidelines place these biologics on equal footing and no longer require that patients fail older immunosuppressive drugs before trying them.
For active lupus nephritis, treatment is more intensive. The standard approach combines an immunosuppressive drug with steroids, and newer protocols add a biologic on top to improve kidney outcomes.
Common Flare Triggers
Ultraviolet light is the most well-established trigger for lupus flares. Even low-level indoor exposure from fluorescent and incandescent bulbs can be enough to provoke symptoms. Daily sunscreen use is essential regardless of whether you plan to go outside. Switching indoor lighting to LED bulbs, which emit minimal UV, and wearing a wide-brimmed hat outdoors are practical steps that make a real difference.
Cigarette smoke contains hydrazine, a known flare trigger. Quitting smoking is one of the most impactful things a person with SLE can do. Certain medications can also provoke flares, particularly sulfa antibiotics (commonly prescribed for urinary tract infections). Carrying a list of your medications and drug allergies, with sulfa antibiotics noted, helps prevent accidental prescriptions. Some herbal supplements, particularly echinacea, stimulate the immune system and can worsen lupus activity.
Beyond avoiding triggers, the most effective prevention strategies are straightforward: taking medications consistently even when you feel well, learning to recognize your personal early warning signs of a flare, and having a flare action plan already in place with your doctor so you can respond quickly rather than waiting for symptoms to escalate.
Long-Term Outlook
Survival rates for SLE have improved substantially over the past several decades. Five-year survival now sits around 91 to 93 percent, with 10-year survival at 83 to 85 percent and 20-year survival around 69 percent. These numbers continue to improve as newer treatments become available.
The leading causes of death in SLE have shifted over time. In Western countries, cardiovascular disease and cancer are now the top causes of mortality, accounting for roughly half of all deaths. This reflects both better control of the disease itself and the long-term cardiovascular toll of chronic inflammation and steroid use. Infections remain the leading cause of death in parts of Asia and South America, likely reflecting differences in treatment access and the heavier use of immunosuppressive drugs in populations with more severe disease. For people living with SLE, managing cardiovascular risk factors like blood pressure, cholesterol, and smoking is just as important as controlling the lupus itself.